Oncology Small Molecule Drugs Market
Oncology Small Molecule Drugs Market Analysis, By Drug Class (Chemotherapy, Immunomodulating, Targeted Therapy Drugs), By Indication (NSCLC, Renal Cell Carcinoma, Breast Cancer), By RoA (Oral, Injectable), By Distribution Channel, By Region - Global Insights to 2032
Analysis of Oncology Small Molecule Drugs market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Oncology Small Molecule Drugs Market Outlook (2022 to 2032)
The global oncology small molecule drugs market has reached a valuation of US$ 79 billion in 2022 and is forecasted to expand at a CAGR of 5.5% to climb to a market size of US$ 135.4 billion by 2032.
North America leads the global oncology small molecule drugs market and is expected to contribute more than 50% share over the assessment period (2022 to 2032).
| Report Attributes | Details |
|---|---|
| Oncology Small Molecule Drugs Market Size (2021A) | US$ 74.3 Billion |
| Estimated Market Value (2022E) | US$ 79 Billion |
| Forecasted Market Value (2032F) | US$ 135.4 Billion |
| Global Market Growth Rate (2022 to 2032) | 5.5% CAGR |
| North America Market Share (2021) | ~48.2% |
| East Asia Market Growth Rate (2022 to 2032) | ~5.2% CAGR |
| United States Market Growth Rate (2022 to 2032) | ~5.5% CAGR |
| Market Share of Top 5 Companies | ~26.7% |
| Key Companies Profiled | Novartis AG; Pfizer Inc.; Amgen Plc.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Sanofi SA; Bristol-Myers Squibb Company; AbbVie Inc.; Bayer AG; Incyte Corporation; Celgene Corporation; AstraZeneca Plc.; Exelixis Inc.; Millennium Pharmaceuticals Inc. (Takeda) |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Analysis of Sales of Oncology Small Molecule Drugs (2017 to 2021) Vs. Market Estimations (2022 to 2032)
Over the past few decades, technological advancements in cancer treatment have captured the attention of the global healthcare community. Since it is the second-leading cause of death worldwide, cancer treatment has traditionally been prioritized by government, non-government, and private organizations.
The development of techniques to test chemicals using transplantable tumors led to the beginning of the use of chemotherapy to treat cancer at the turn of the 20th century. Epigenetic and environmental variables play a significant role in the development of tumors, in addition to genetic changes in cancer cells.
Traditional medicines have proven successful in treating cancer; however, because of their non-specific activity on both normal and malignant cells, they frequently produced negative side effects. As a result, small molecule inhibitor-based tailored therapeutic approaches are being thoroughly researched.
The inevitable need for targeted drug development to cure fatal diseases such as cancer has encouraged the pharmaceutical industry to come up with various treatment solutions, which has created opportunistic growth prospects for the pharmaceutical market at a compound annual growth rate of 5.5% from 2022 to 2032.
The development of small molecule medicines for cancer therapies in present times is revolutionary and has completely changed the landscape of cancer therapy. Small molecule medications have made such significant advancements that they have surpassed all other consequential advancements in the field of cancer therapeutics, including immune cells and radiation therapy.
The popularity of small molecule cancer medications is steadily rising due to factors such as better overall results, minimal drawbacks, earlier treatment initiation, small drug sizes, etc. Small molecule cancer medications have all of the aforementioned important advantages over other traditional immunotherapies, and the identified clinical trial landscape for them concludes their significance and demand to be thought of as standard therapy.
Owing to these beneficial factors, the oncology small molecule drugs market is expected to offer an absolute $ opportunity of US$ 61.1 billion between 2022 and 2032.
- Short Term (2022 to 2025): Adoption of small molecule drugs for the treatment of cancer has significantly driven the global market as these drugs notably reduced the mortality rate by overcoming limitations of conventional cancer therapies such as radiation therapy and chemotherapy.
- Medium Term (2025 to 2028): Improved healthcare services and increment in per-capita spending on healthcare in underdeveloped regions will further contribute to an increase in the sales of small molecule drugs. Regions such as East Asia and MEA will witness incremental opportunistic growth.
- Long Term (2028 to 2032): Small molecule drug demand is forecasted to rise globally due to rigorous research and development in the field of cancer. Personalized targeted drug production and new product launches, along with regulatory approvals, will drive the growth of the market.
Between 2017 and 2021, consumption of oncology small molecule drugs increased at a CAGR of 5.4%. As per the study by Fact.MR, a market research and competitive intelligence provider, the market is projected to progress at 5.5% CAGR between 2022 and 2032.
Market share analysis of oncology small molecule drugs based on drug class, and region. Targeted therapy drugs occupy 51.2% market share by drug class in 2022.
What is the Scenario for the Demand for Oncology Small Molecule Drugs?
“New & Effective Drug Launches and Vigorous Product Pipelines”
The popularity of small molecule cancer medications is steadily rising among patients due to an increase in the occurrence of cancer cases. Small molecule drugs are recorded to have better overall results, with minimal drawbacks, earlier treatment initiation, small drug sizes, etc.
Small molecule cancer medications have all of the aforesaid important advantages over other traditional immunotherapies, and recognized clinical trials support their significance and need to be thought of as standard therapy.
There are more than 2,500 small molecule cancer medications undergoing clinical studies at the moment. A majority of medications are in the preclinical stage, which is followed by Phase-I clinical trials. Currently, there are more than 200 small molecule cancer medications.
Modern technology is being incorporated by manufacturers to lower cancer risks and improve its therapy. Additionally, to lower the death rate, governments are funding the development of sophisticated cancer drugs that are affordable and widely accessible.
“High Drug Manufacturing & Purchasing Costs Affecting Both Producers and Consumers”
The small molecule oncology medication industry has a highly competitive and consolidated vendor landscape. Because oncology small molecule medications are a relatively new class of cancer therapeutics, they require a high level of clinical competence and are expensive; hence, only a few major pharmaceutical companies produce these kinds of drugs.
To conduct these delicate studies, pharmaceutical companies need contemporary, well-equipped research laboratories. Another constraint on producers is the delay in regulatory and drug federation approval of products followed by successful clinical trials. Increased medicine manufacturing and launch costs will have an immediate impact on the prices of final products. Higher medicine prices may distract the attention of the world's middle-class population, which could eventually result in manufacturers’ revenue and resource loss.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
Will Progression of Healthcare Sector in the U.S. Drive High Demand for Oncology Small Molecule Drugs?
- According to the American Cancer Society, 1.8 million new instances of cancer will be diagnosed nationwide in 2020, with 606,520 deaths.
Pharmaceutical corporations are seeking quicker approvals of their potential therapeutic candidates. The FDA's subsequent clearance of cancer medications has opened up new markets for oncology-specific medications in the nation. Manufacturers are also concentrating on technological developments in the medication development cycle, which will maximize the discovery of novel and efficient medicines.
With a high percentage of cancer patients seeking treatment and favorable reimbursement policies provided by insurance companies, North America is anticipated to generate US$ 38.1 billion in revenue in 2022.
Why is the East Asia Oncology Small Molecule Drug Market Flourishing?
China and Japan are two of the biggest East Asian nations, and together, they contribute to a significant market share in both technology and healthcare. China is second in the global market, accounting for nearly 30% of all lung cancer cases, 40% of stomach cancer cases, and 50% of liver cancer cases worldwide, in its oncology market alone. Furthermore, China has a death rate from cancer that is 40% higher than the U.S. average.
- 'Elunate', a colon cancer treatment, just gained China's first full approval of a drug developed following contemporary clinical studies (fruquintinib).
This will promote the growth of the nation's small molecule oncology drugs market. East Asia is expected to generate US$ 16.7 billion in revenue in 2032.
Category-wise Insights
Why is Oral Route of Administration Most Popular for Drug Intake?
The oral route of administration is widely preferred by patients as oral drugs are easy to consume and monitor and patients do not require any specialized training to administer the drug. Besides, they are economical as it does not require extra expenditure spending.
Owing to their several advantages, oral targeted treatments are most generously being utilised to treat cancer. They function by obstructing particular chemicals or processes that contribute to the formation of tumors. Currently, targeted drug delivery is proving to be a successful strategy for oral therapeutic drug delivery.
Why are Drugs for Targeted Therapy Becoming a Dominant Drug Class?
Since targeted therapy can help prevent cancer cells from reproducing, it is becoming an increasingly important type of cancer treatment. Targeted treatment medications are anticipated to account for 50% of global sales, according to Fact.MR.
Oncology small molecule medications that target a particular genetic mutation known as NTRK fusion, such as larotrectinib (Vitrakvi), are steadily receiving FDA approvals, which will boost their market share.
A growing number of small-molecule targeted medicines have been created for the treatment of malignancies.
- The U.S. Food and Drug Administration (FDA) approved the first tyrosine kinase inhibitor 'imatinib' for market sales in 2001.
Targeted medications have emerged and proliferated quickly in the market owing to their several benefits.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Several well-known market players are adopting novel strategies, including ground-breaking marketing strategies, technical developments, mergers, and acquisitions.
Market players such as Novartis AG, Pfizer Inc., Amgen Plc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc., Bayer AG, Incyte Corporation, Celgene Corporation, AstraZeneca Plc., Exelixis Inc., and Millennium Pharmaceuticals Inc. (Takeda) are utilising sustainable technology and optimization strategies for a variety of end users.
Additionally, manufacturers’ primary marketing plans are based on their expertise in planning, coming up with, and delivering the best solutions. Manufacturers in the market also want to expand their product distribution into developing and low-income nations.
- The U.S. Food and Drug Administration granted Novartis AG's Lu-PSMA-617, an investigational radiation therapy for advanced castration-resistant prostate cancer, the classification of 'breakthrough therapy', in June 2021.
- Sanofi and Synthorx, Inc., a clinical-stage biotechnology firm devoted to extending and enhancing the lives of people with cancer and autoimmune illnesses, entered into a formal deal worth roughly US$ 2.5 billion in December 2019.
Segmentation of Oncology Small Molecule Drugs Industry Research
-
By Drug Class :
- Chemotherapy Drugs
- Alkylating Agents
- Antimetabolites
- Other Drugs
- Immunomodulating Drugs
- Targeted Therapy Drugs
- Proteasome Inhibitors
- Tyrosine Kinase Inhibitors
- mTOR Inhibitors
- Others
- Hormonal Therapy
- Chemotherapy Drugs
-
By Indication :
- NSCLC
- Renal Cell Carcinoma
- Breast Cancer
- Prostate Cancer
- Multiple Myeloma
- Melanoma
- Lymphoma
- Leukemia
- Others
-
By RoA :
- Oral
- Injectable
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Clinics
- Online Pharmacies
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & ASEAN
- Oceania
- MEA
Table of Content
- 1. Market - Executive Summary
- 2. Market Overview
- 3. Market Background and Foundation Data
- 4. Global Market Value (US$ Billion) Analysis and Forecast
- 5. Global Market Analysis and Forecast, By Drug Class
- 5.1 Chemotherapy Drugs
- 5.1.1 Alkylating Agents
- 5.1.2 Antimetabolites
- 5.1.3 Other Drugs
- 5.2 Immunomodulating Drugs
- 5.3 Targeted Therapy Drugs
- 5.3.1 Proteasome Inhibitors
- 5.3.2 Tyrosine Kinase Inhibitors
- 5.3.3 mTOR Inhibitors
- 5.3.4 Others
- 5.4 Hormonal Therapy
- 5.1 Chemotherapy Drugs
- 6. Global Market Analysis and Forecast, By Indication
- 6.1 NSCLC
- 6.2 Renal Cell Carcinoma
- 6.3 Breast Cancer
- 6.4 Prostate Cancer
- 6.5 Multiple Myeloma
- 6.6 Melanoma
- 6.7 Lymphoma
- 6.8 Leukemia
- 6.9 Others
- 7. Global Market Analysis and Forecast, By Route of Administration
- 7.1 Oral
- 7.2 Injectable
- 8. Global Market Analysis and Forecast, By Distribution Channel
- 8.1 Hospital Pharmacies
- 8.2 Retail Pharmacies
- 8.3 Specialty Clinics
- 8.4 Online Pharmacies
- 9. Global Market Analysis and Forecast, By Region
- 9.1 North America
- 9.2 Latin America
- 9.3 Europe
- 9.4 East Asia
- 9.5 South Asia & ASEAN
- 9.6 Oceania
- 9.7 Middle East & Africa
- 10. North America Market Analysis and Forecast
- 11. Latin America Market Analysis and Forecast
- 12. Europe Market Analysis and Forecast
- 13. East Asia Market Analysis and Forecast
- 14. South Asia & ASEAN Market Analysis and Forecast
- 15. Oceania Market Analysis and Forecast
- 16. Middle East & Africa Market Analysis and Forecast
- 17. Country-level Market Analysis and Forecast
- 18. Market Structure Analysis
- 19. Competition Analysis
- 19.1 Novartis AG
- 19.2 Pfizer Inc.
- 19.3 Amgen Plc.
- 19.4 F. Hoffmann-La Roche Ltd.
- 19.5 Eli Lilly and Company
- 19.6 Sanofi SA
- 19.7 Bristol-Myers Squibb Company
- 19.8 AbbVie Inc.
- 19.9 Bayer AG
- 19.10 Incyte Corporation
- 19.11 Celgene Corporation
- 19.12 AstraZeneca Plc.
- 19.13 Exelixis Inc.
- 19.14 Millennium Pharmaceuticals Inc. (Takeda)
- 20. Assumptions & Acronyms Used
- 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (USD Billion) and Forecast by Region, 2017 to 2021
Table 02: Global Market Value (USD Billion) and Forecast by Region, 2022 to 2032
Table 03: Global Market Value (USD Billion) and Forecast by Drug Class, 2017 to 2021
Table 04: Global Market Value (USD Billion) and Forecast by Drug Class, 2022 to 2032
Table 05: Global Market Value (USD Billion) and Forecast by Indication, 2017 to 2021
Table 06: Global Market Value (USD Billion) and Forecast by Indication, 2022 to 2032
Table 07: Global Market Value (USD Billion) and Forecast by Route of Administration, 2017 to 2021
Table 08: Global Market Value (USD Billion) and Forecast by Route of Administration, 2022 to 2032
Table 09: Global Market Value (USD Billion) and Forecast by Distribution Channel, 2017 to 2021
Table 10: Global Market Value (USD Billion) and Forecast by Distribution Channel, 2022 to 2032
Table 11: North America Market Value (USD Billion) and Forecast by Country, 2017 to 2021
Table 12: North America Market Value (USD Billion) and Forecast by Country, 2022 to 2032
Table 13: North America Market Value (USD Billion) and Forecast by Drug Class, 2017 to 2021
Table 14: North America Market Value (USD Billion) and Forecast by Drug Class, 2022 to 2032
Table 15: North America Market Value (USD Billion) and Forecast by Indication, 2017 to 2021
Table 16: North America Market Value (USD Billion) and Forecast by Indication, 2022 to 2032
Table 17: North America Market Value (USD Billion) and Forecast by Route of Administration, 2017 to 2021
Table 18: North America Market Value (USD Billion) and Forecast by Route of Administration, 2022 to 2032
Table 19: North America Market Value (USD Billion) and Forecast by Distribution Channel, 2017 to 2021
Table 20: North America Market Value (USD Billion) and Forecast by Distribution Channel, 2022 to 2032
Table 21: Latin America Market Value (USD Billion) and Forecast by Country, 2017 to 2021
Table 22: Latin America Market Value (USD Billion) and Forecast by Country, 2022 to 2032
Table 23: Latin America Market Value (USD Billion) and Forecast by Drug Class, 2017 to 2021
Table 24: Latin America Market Value (USD Billion) and Forecast by Drug Class, 2022 to 2032
Table 25: Latin America Market Value (USD Billion) and Forecast by Indication, 2017 to 2021
Table 26: Latin America Market Value (USD Billion) and Forecast by Indication, 2022 to 2032
Table 27: Latin America Market Value (USD Billion) and Forecast by Route of Administration, 2017 to 2021
Table 28: Latin America Market Value (USD Billion) and Forecast by Route of Administration, 2022 to 2032
Table 29: Latin America Market Value (USD Billion) and Forecast by Distribution Channel, 2017 to 2021
Table 30: Latin America Market Value (USD Billion) and Forecast by Distribution Channel, 2022 to 2032
Table 31: Europe Market Value (USD Billion) and Forecast by Country, 2017 to 2021
Table 32: Europe Market Value (USD Billion) and Forecast by Country, 2022 to 2032
Table 33: Europe Market Value (USD Billion) and Forecast by Drug Class, 2017 to 2021
Table 34: Europe Market Value (USD Billion) and Forecast by Drug Class, 2022 to 2032
Table 35: Europe Market Value (USD Billion) and Forecast by Indication, 2017 to 2021
Table 36: Europe Market Value (USD Billion) and Forecast by Indication, 2022 to 2032
Table 37: Europe Market Value (USD Billion) and Forecast by Route of Administration, 2017 to 2021
Table 38: Europe Market Value (USD Billion) and Forecast by Route of Administration, 2022 to 2032
Table 39: Europe Market Value (USD Billion) and Forecast by Distribution Channel, 2017 to 2021
Table 40: Europe Market Value (USD Billion) and Forecast by Distribution Channel, 2022 to 2032
Table 41: East Asia Market Value (USD Billion) and Forecast by Country, 2017 to 2021
Table 42: East Asia Market Value (USD Billion) and Forecast by Country, 2022 to 2032
Table 43: East Asia Market Value (USD Billion) and Forecast by Drug Class, 2017 to 2021
Table 44: East Asia Market Value (USD Billion) and Forecast by Drug Class, 2022 to 2032
Table 45: East Asia Market Value (USD Billion) and Forecast by Indication, 2017 to 2021
Table 46: East Asia Market Value (USD Billion) and Forecast by Indication, 2022 to 2032
Table 47: East Asia Market Value (USD Billion) and Forecast by Route of Administration, 2017 to 2021
Table 48: East Asia Market Value (USD Billion) and Forecast by Route of Administration, 2022 to 2032
Table 49: East Asia Market Value (USD Billion) and Forecast by Distribution Channel, 2017 to 2021
Table 50: East Asia Market Value (USD Billion) and Forecast by Distribution Channel, 2022 to 2032
Table 51: South Asia & ASEAN Market Value (USD Billion) and Forecast by Country, 2017 to 2021
Table 52: South Asia & ASEAN Market Value (USD Billion) and Forecast by Country, 2022 to 2032
Table 53: South Asia & ASEAN Market Value (USD Billion) and Forecast by Drug Class, 2017 to 2021
Table 54: South Asia & ASEAN Market Value (USD Billion) and Forecast by Drug Class, 2022 to 2032
Table 55: South Asia & ASEAN Market Value (USD Billion) and Forecast by Indication, 2017 to 2021
Table 56: South Asia & ASEAN Market Value (USD Billion) and Forecast by Indication, 2022 to 2032
Table 57: South Asia & ASEAN Market Value (USD Billion) and Forecast by Route of Administration, 2017 to 2021
Table 58: South Asia & ASEAN Market Value (USD Billion) and Forecast by Route of Administration, 2022 to 2032
Table 59: South Asia & ASEAN Market Value (USD Billion) and Forecast by Distribution Channel, 2017 to 2021
Table 60: South Asia & ASEAN Market Value (USD Billion) and Forecast by Distribution Channel, 2022 to 2032
Table 61: Oceania Market Value (USD Billion) and Forecast by Country, 2017 to 2021
Table 62: Oceania Market Value (USD Billion) and Forecast by Country, 2022 to 2032
Table 63: Oceania Market Value (USD Billion) and Forecast by Drug Class, 2017 to 2021
Table 64: Oceania Market Value (USD Billion) and Forecast by Drug Class, 2022 to 2032
Table 65: Oceania Market Value (USD Billion) and Forecast by Indication, 2017 to 2021
Table 66: Oceania Market Value (USD Billion) and Forecast by Indication, 2022 to 2032
Table 67: Oceania Market Value (USD Billion) and Forecast by Route of Administration, 2017 to 2021
Table 68: Oceania Market Value (USD Billion) and Forecast by Route of Administration, 2022 to 2032
Table 69: Oceania Market Value (USD Billion) and Forecast by Distribution Channel, 2017 to 2021
Table 70: Oceania Market Value (USD Billion) and Forecast by Distribution Channel, 2022 to 2032
Table 71: MEA Market Value (USD Billion) and Forecast by Country, 2017 to 2021
Table 72: MEA Market Value (USD Billion) and Forecast by Country, 2022 to 2032
Table 73: MEA Market Value (USD Billion) and Forecast by Drug Class, 2017 to 2021
Table 74: MEA Market Value (USD Billion) and Forecast by Drug Class, 2022 to 2032
Table 75: MEA Market Value (USD Billion) and Forecast by Indication, 2017 to 2021
Table 76: MEA Market Value (USD Billion) and Forecast by Indication, 2022 to 2032
Table 77: MEA Market Value (USD Billion) and Forecast by Route of Administration, 2017 to 2021
Table 78: MEA Market Value (USD Billion) and Forecast by Route of Administration, 2022 to 2032
Table 79: MEA Market Value (USD Billion) and Forecast by Distribution Channel, 2017 to 2021
Table 80: MEA Market Value (USD Billion) and Forecast by Distribution Channel, 2022 to 2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (USD Billion) Forecast, 2022 to 2032
Figure 02: Global Market Absolute $ Opportunity (USD Billion), 2022 to 2032
Figure 03: Global Market Value (USD Billion) by Region, 2022 & 2032
Figure 04: Global Market Y-o-Y Growth Rate by Region, 2022 to 2032
Figure 05: Global Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 06: Global Market Y-o-Y Growth Rate by Drug Class, 2022 to 2032
Figure 07: Global Market Value (USD Billion) by Indication, 2022 & 2032
Figure 08: Global Market Y-o-Y Growth Rate by Indication, 2022 to 2032
Figure 09: Global Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 10: Global Market Y-o-Y Growth Rate by Route of Administration, 2022 to 2032
Figure 11: Global Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 12: Global Market Y-o-Y Growth Rate by Distribution Channel, 2022 to 2032
Figure 13: North America Market Value (USD Billion) Forecast, 2022 to 2032
Figure 14: North America Market Absolute $ Opportunity (USD Billion), 2022 to 2032
Figure 15: North America Market Value (USD Billion) by Country, 2022 & 2032
Figure 16: North America Market Y-o-Y Growth Rate by Country, 2022 to 2032
Figure 17: North America Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 18: North America Market Y-o-Y Growth Rate by Drug Class, 2022 to 2032
Figure 19: North America Market Value (USD Billion) by Indication, 2022 & 2032
Figure 20: North America Market Y-o-Y Growth Rate by Indication, 2022 to 2032
Figure 21: North America Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 22: North America Market Y-o-Y Growth Rate by Route of Administration, 2022 to 2032
Figure 23: North America Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 24: North America Market Y-o-Y Growth Rate by Distribution Channel, 2022 to 2032
Figure 25: North America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 26: North America Market Attractiveness Analysis by Drug Class, 2022 to 2032
Figure 27: North America Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 28: North America Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 29: North America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 30: Latin America Market Value (USD Billion) Forecast, 2022 to 2032
Figure 31: Latin America Market Absolute $ Opportunity (USD Billion), 2022 to 2032
Figure 32: Latin America Market Value (USD Billion) by Country, 2022 & 2032
Figure 33: Latin America Market Y-o-Y Growth Rate by Country, 2022 to 2032
Figure 34: Latin America Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 35: Latin America Market Y-o-Y Growth Rate by Drug Class, 2022 to 2032
Figure 36: Latin America Market Value (USD Billion) by Indication, 2022 & 2032
Figure 37: Latin America Market Y-o-Y Growth Rate by Indication, 2022 to 2032
Figure 38: Latin America Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 39: Latin America Market Y-o-Y Growth Rate by Route of Administration, 2022 to 2032
Figure 40: Latin America Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 41: Latin America Market Y-o-Y Growth Rate by Distribution Channel, 2022 to 2032
Figure 42: Latin America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 43: Latin America Market Attractiveness Analysis by Drug Class, 2022 to 2032
Figure 44: Latin America Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 45: Latin America Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 46: Latin America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 47: Europe Market Value (USD Billion) Forecast, 2022 to 2032
Figure 48: Europe Market Absolute $ Opportunity (USD Billion), 2022 to 2032
Figure 49: Europe Market Value (USD Billion) by Country, 2022 & 2032
Figure 50: Europe Market Y-o-Y Growth Rate by Country, 2022 to 2032
Figure 51: Europe Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 52: Europe Market Y-o-Y Growth Rate by Drug Class, 2022 to 2032
Figure 53: Europe Market Value (USD Billion) by Indication, 2022 & 2032
Figure 54: Europe Market Y-o-Y Growth Rate by Indication, 2022 to 2032
Figure 55: Europe Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 56: Europe Market Y-o-Y Growth Rate by Route of Administration, 2022 to 2032
Figure 57: Europe Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 58: Europe Market Y-o-Y Growth Rate by Distribution Channel, 2022 to 2032
Figure 59: Europe Market Attractiveness Analysis by Country, 2022 to 2032
Figure 60: Europe Market Attractiveness Analysis by Drug Class, 2022 to 2032
Figure 61: Europe Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 62: Europe Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 63: Europe Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 64: East Asia Market Value (USD Billion) Forecast, 2022 to 2032
Figure 65: East Asia Market Absolute $ Opportunity (USD Billion), 2022 to 2032
Figure 66: East Asia Market Value (USD Billion) by Country, 2022 & 2032
Figure 67: East Asia Market Y-o-Y Growth Rate by Country, 2022 to 2032
Figure 68: East Asia Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 69: East Asia Market Y-o-Y Growth Rate by Drug Class, 2022 to 2032
Figure 70: East Asia Market Value (USD Billion) by Indication, 2022 & 2032
Figure 71: East Asia Market Y-o-Y Growth Rate by Indication, 2022 to 2032
Figure 72: East Asia Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 73: East Asia Market Y-o-Y Growth Rate by Route of Administration, 2022 to 2032
Figure 74: East Asia Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 75: East Asia Market Y-o-Y Growth Rate by Distribution Channel, 2022 to 2032
Figure 76: East Asia Market Attractiveness Analysis by Country, 2022 to 2032
Figure 77: East Asia Market Attractiveness Analysis by Drug Class, 2022 to 2032
Figure 78: East Asia Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 79: East Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 80: East Asia Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 81: South Asia & ASEAN Market Value (USD Billion) Forecast, 2022 to 2032
Figure 82: South Asia & ASEAN Market Absolute $ Opportunity (USD Billion), 2022 to 2032
Figure 83: South Asia & ASEAN Market Value (USD Billion) by Country, 2022 & 2032
Figure 84: South Asia & ASEAN Market Y-o-Y Growth Rate by Country, 2022 to 2032
Figure 85: South Asia & ASEAN Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 86: South Asia & ASEAN Market Y-o-Y Growth Rate by Drug Class, 2022 to 2032
Figure 87: South Asia & ASEAN Market Value (USD Billion) by Indication, 2022 & 2032
Figure 88: South Asia & ASEAN Market Y-o-Y Growth Rate by Indication, 2022 to 2032
Figure 89: South Asia & ASEAN Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 90: South Asia & ASEAN Market Y-o-Y Growth Rate by Route of Administration, 2022 to 2032
Figure 91: South Asia & ASEAN Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 92: South Asia & ASEAN Market Y-o-Y Growth Rate by Distribution Channel, 2022 to 2032
Figure 93: South Asia & ASEAN Market Attractiveness Analysis by Country, 2022 to 2032
Figure 94: South Asia & ASEAN Market Attractiveness Analysis by Drug Class, 2022 to 2032
Figure 95: South Asia & ASEAN Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 96: South Asia & ASEAN Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 97: South Asia & ASEAN Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 98: Oceania Market Value (USD Billion) Forecast, 2022 to 2032
Figure 99: Oceania Market Absolute $ Opportunity (USD Billion), 2022 to 2032
Figure 100: Oceania Market Value (USD Billion) by Country, 2022 & 2032
Figure 101: Oceania Market Y-o-Y Growth Rate by Country, 2022 to 2032
Figure 102: Oceania Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 103: Oceania Market Y-o-Y Growth Rate by Drug Class, 2022 to 2032
Figure 104: Oceania Market Value (USD Billion) by Indication, 2022 & 2032
Figure 105: Oceania Market Y-o-Y Growth Rate by Indication, 2022 to 2032
Figure 106: Oceania Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 107: Oceania Market Y-o-Y Growth Rate by Route of Administration, 2022 to 2032
Figure 108: Oceania Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 109: Oceania Market Y-o-Y Growth Rate by Distribution Channel, 2022 to 2032
Figure 110: Oceania Market Attractiveness Analysis by Country, 2022 to 2032
Figure 111: Oceania Market Attractiveness Analysis by Drug Class, 2022 to 2032
Figure 112: Oceania Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 113: Oceania Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 114: Oceania Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Figure 115: MEA Market Value (USD Billion) Forecast, 2022 to 2032
Figure 116: MEA Market Absolute $ Opportunity (USD Billion), 2022 to 2032
Figure 117: MEA Market Value (USD Billion) by Country, 2022 & 2032
Figure 118: MEA Market Y-o-Y Growth Rate by Country, 2022 to 2032
Figure 119: MEA Market Value (USD Billion) by Drug Class, 2022 & 2032
Figure 120: MEA Market Y-o-Y Growth Rate by Drug Class, 2022 to 2032
Figure 121: MEA Market Value (USD Billion) by Indication, 2022 & 2032
Figure 122: MEA Market Y-o-Y Growth Rate by Indication, 2022 to 2032
Figure 123: MEA Market Value (USD Billion) by Route of Administration, 2022 & 2032
Figure 124: MEA Market Y-o-Y Growth Rate by Route of Administration, 2022 to 2032
Figure 125: MEA Market Value (USD Billion) by Distribution Channel, 2022 & 2032
Figure 126: MEA Market Y-o-Y Growth Rate by Distribution Channel, 2022 to 2032
Figure 127: MEA Market Attractiveness Analysis by Country, 2022 to 2032
Figure 128: MEA Market Attractiveness Analysis by Drug Class, 2022 to 2032
Figure 129: MEA Market Attractiveness Analysis by Indication, 2022 to 2032
Figure 130: MEA Market Attractiveness Analysis by Route of Administration, 2022 to 2032
Figure 131: MEA Market Attractiveness Analysis by Distribution Channel, 2022 to 2032
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
Which segment accounts for the highest revenue generation?
Targeted therapy drugs account for 50.8% share, the highest in the global market.
How is the market anticipated to perform over the decade?
Sales of oncology small molecule drugs are anticipated to increase at 5.5% CAGR and reach US$ 135.4 billion by 2032.
What is the revenue of the oncology small molecule drugs market?
The global oncology small molecule drugs market is valued at US$ 79 billion in 2022.
Which regional market is being eyed by most manufacturers?
North America tops the global oncology small molecule drugs market accounting for 48.2% market share in 2021.
How did the market perform over the past few years?
From 2017 to 2021, consumption of oncology small molecule drugs increased at 5.4% CAGR.
Oncology Small Molecule Drugs Market